Therapeutic Advances in Psychopharmacology
December 11, 2025
Casimiro Cabrera Abreu, Aleksandar Biorac, Ross J. Baldessarini et al.
Ketamine’s development in psychiatry exemplifies the evolution of psychopharmacology over six decades. Originally introduced as a dissociative anesthetic and psychotomimetic probe, ketamine has been repositioned as a rapidly acting antidepressant, particularly for treatment-resistant depression (TRD). This narrative review draws on historical sources, clinical trials, regulatory documents, and...
CNS & Neurological Disorders - Drug Targets
2017
Gustavo Vazquez, Sebastian Camino, Leonardo Tondo et al.
Treatments for depression in bipolar disorder (BD) are far less well developed than for unipolar major depressive disorder. Several innovative and experimental approaches have been emerging recently, including use of the dissociative anesthetic ketamine and other antagonists of central NMDA glutamate receptors, as well as unsaturated fatty acids, anti-inflammatory agents, and possibly probiotic...
Psychopharmacology
1979
R. Malcolm Stewart, Alexander Campbell, Günther Sperk et al.
43 citations
Muscle twitches and autonomic changes were induced by systemic injections of L -5-hydroxytryptophan (5-HTP) or the serotonin agonist 5-methoxy- N,N -dimethyltryptamine (5-MeO-DMT) in rats previously lesioned with intracranial 5,7-dihydroxytryptamine (5,7-DHT) after desmethylimipramine. Movements were recorded sensitively and continuously by an electronic activity monitor. Spontaneous locomotor...
Journal of Neurochemistry
October 1, 1978
Giorgio Stramentinoli, Ross J. Baldessarini
Abstract In vivo conversion of intracisternally administered [14C]tryptamine to [14C]N,N‐dimethyl‐tryptamine (DMT) in rat brain, even in the presence of an excess of substrate and methyl donor appeared to be insignificant, although enzymatically synthesized [14C]DMT was recovered readily after intracranial injection. Authenticity of [14C]DMT was demonstrated by cocrystallization with authentic...